| INTRODUCTION
Neutralizing antibodies against exogenous clotting factor VIII (FVIII) remain the most significant treatment complication in patients with haemophilia A (HA), particularly in previously untreated patients (PUPs) with severe HA. 1 Inhibitor development is mediated by a complex interaction of unmodifiable host-related factors (eg HA severity, family history, ethnicity, specific F8 gene mutations) and potentially modifiable treatment-related factors, including product type and treatment intensity. 1, 2 The European Medicines Agency (EMA) recognizes that the origin and nature of an active biologic protein, major modifications to that protein and product-or process-related impurities may affect the risk profile of a biologic protein therapy. HA. 4 The majority of inhibitors arise within 20 exposure days (EDs). [4] [5] [6] [7] Patients developed inhibitors after a median of 14 EDs (interquartile range [IQR], 8-19 days) in one study 5 and after a median of 15 EDs (IQR, 10-20 days) in another. 7 Some reports have suggested a higher inhibitor incidence with recombinant FVIII (rFVIII) products than with plasma-derived FVIII concentrates (pdFVIII), while other studies did not. 4, [7] [8] [9] However, none of these studies included rFVIII products produced in human cell lines. 
| METHODS

| Study design and patients
The NuProtect study (NCT01712438) is an ongoing, prospective, mul- Parents/legal guardians provided written consent before patients entered the study.
| Study treatment
Patients received Nuwiq ® for standard prophylaxis or on-demand treatment, and for treatment of breakthrough bleeds or surgical prophylaxis, as required. No FVIII concentrates other than Nuwiq ® were used in the study. Prophylactic treatment was recommended;
however, the responsible treating physician decided whether patients were treated prophylactically or on-demand. Patients could switch between on-demand and prophylactic treatment during the course of the study. The recommended dose for standard prophylaxis was 20-50 IU FVIII kg −1 , however frequency and dosing depended on the patient's clinical situation and were at the investigator's discretion.
The dosage and duration for treating breakthrough bleeds, ondemand treatment and during surgical prophylaxis depended on the location and extent of bleeding, and on the clinical condition of the patient.
| Outcome measures
The primary endpoint of the study is inhibitor activity after Nuwiq were recorded throughout the study.
| Statistical analyses
Statistical analyses of all endpoints were exploratory and were performed by Accovion GmbH (Marburg, Germany). Cumulative inhibitor rates and 95% confidence intervals (CIs) were calculated using Kaplan-Meier methods. In addition to mean ± standard deviation (SD) and median (range) ABR values, ABRs and 95% CIs were calculated using a Poisson model.
| RESULTS
| Patient disposition
Eighty-five PUPs treated with Nuwiq ® were included in the first preplanned interim analysis in May 2016, 66 of whom had ≥20 EDs Table 1 . F8 gene mutation analysis data were available for 59 patients, of whom 58 had identifiable mutations:
44/58 patients (75.9%) had known high-risk mutations and 47/58 patients (81.0%) had null mutations.
| Immunogenicity
Positive anti-FVIII inhibitor titres (≥0.6 BU) were reported for 13/66 (19.7%) patients (Table 1) ; 8 (12.1%) were HT inhibitors, and 5 (7.6%)
were LT inhibitors. Of the LT inhibitors, 4/5 (80%) were transient. The
T A B L E 1 Patient and treatment characteristics by inhibitor titre group and overall
Parameter
High-titre inhibitors N=8
Low-titre inhibitors N=5
Any inhibitors N=13
No inhibitors N=53
All patients N=66
Age at first treatment, months median (range) ) before inhibitor appearance. f Low treatment intensity defined as having no peak treatment moments. High treatment intensity defined as having peak treatment moments. Twelve of the 13 patients with an inhibitor had detectable F8 gene mutations; all were null mutations, and 11 were high-risk. Efficacy of treatment was rated as "excellent" or "good" for 324/353 (91.8%) of rated bleeds during inhibitor-free periods (Table 4) .
| Efficacy
| Prevention of bleeds during prophylaxis
| Treatment of bleeds
| Surgical prophylaxis
Thirteen children underwent 14 planned surgical procedures covered with Nuwiq ® (Table 5 ). Eleven procedures in 10 patients were minor and 3 procedures in 3 patients were major. Of the 9 rated procedures during inhibitor-free periods, efficacy was "excellent" or "good" in 8 procedures (89%) and "moderate" in 1 procedure (11%).
| In vivo recovery (IVR)
IVR (chromogenic assay) was assessed in the first 6 months in 33 patients during inhibitor-free periods. Mean (SD) IVR was 1.4 (0.6) % per IU kg −1 (median 1.6). 
| Safety
| DISCUSSION
We present here the results from a cohort of patients included in a preplanned interim analysis of the ongoing NuProtect study with a fourth generation human cell line-derived rFVIII. This analysis evaluates 66 PUPs treated with Nuwiq ® for ≥20 EDs (the cut-off was chosen since FVIII inhibitors generally develop within the first 20 exposures to exogenous FVIII). [5] [6] [7] The study will eventually evaluate 110
PUPs in total, making it the largest prospective study in PUPs with a single FVIII product. The cumulative incidence (95% CI) of all and HT inhibitors in NuProtect was 20.8% (10.7%, 31.0%) and 12.8% (4.5%, 21.2%), respectively, with inhibitor incidence remaining at a consistent level throughout the study period.
The 6 largest observational studies that investigated the incidence of inhibitors in PUPs treated with rFVIII produced in hamster cell lines or pdFVIII have reported conflicting results. 6, 7, [19] [20] [21] [22] Three of the studies suggested that the use of pdFVIII products in PUPs was associated with a reduced rate of inhibitors [19] [20] [21] and 3 showed no difference between pdFVIII and rFVIII. 6, 7, 22 These observational studies differed T A B L E 3 Overall efficacy assessment of Nuwiq ® prophylaxis and bleeding rates in terms of study design, patient enrolment criteria, severity of disease, inhibitor definitions, inhibitor detection methods and testing frequency. Recently, the results of the first prospective, randomized, controlled study (the SIPPET study) comparing the immunogenicity of pdFVIII/von Willebrand factor (VWF) and rFVIII products were published. In SIPPET, the cumulative incidence (95% CI) of all and HT inhibitors in patients treated with pdFVIII was 26.8% (18.4%, 35.2%) and 18.6% (11.2%, 26.0%), and in those treated with rFVIII, it was 44.5%
(34.7%, 54.3%) and 28.4% (19.6%, 37.2%) respectively. 4 More than 80% of patients in the NuProtect study had null F8 mutations, indicating that the patients were at high-risk for developing inhibitors. Importantly, the NuProtect study enrolled only true PUPs, ie without prior exposure to FVIII concentrates or any other blood products. Since most inhibitors are detected within the first 20 EDs, [5] [6] [7] patients previously exposed to blood products may exhibit lower risk of inhibitor development than true PUPs. Early development of inhibitors during treatment was observed in NuProtect (median time to development of HT and LT inhibitors was 11.5 and 8.0 days respectively).
Nuwiq ® is produced in a human cell line without chemical modification or protein fusion, with the goal of reducing immunogenicity. [23] [24] [25] It contains only human posttranslational modifications 24 and is free of any added human or animal impurities. 23 Nuwiq ® has been shown to be fully sulphated at Tyr 1680 and to have a higher VWF binding affinity than comparator rFVIII products produced in hamster cell lines. 24 Binding to VWF protects FVIII from degradation, 26 Of the 50 patients who had ≥50 EDs, 12 (cumulative incidence 24.0%; 95% CI: 13.1%, 38.2%) developed inhibitors, and 8 (16.0%; 95% CI:
7.2%, 29.1%) developed HT inhibitors. The inhibitor incidence has remained at a consistent level throughout the study to date.
As almost all patients enrolled across 14 countries in this interim analysis were Caucasian, no data were collected for patients of African descent who are assumed to be at higher risk of inhibitor development, 29, 30 although definitive evidence from comparative studies is not available. A strength of the study is the inclusion of only "true" PUPs, ie without prior exposure to FVIII concentrates or any other blood products. In addition, extensive immunogenicity testing was done throughout the study and all analyses were performed at a central laboratory.
In conclusion, interim data from the NuProtect study show that Criteria for major surgery: requiring general or spinal anaesthesia, requiring opening into the great body cavities, in the course of which hazard of severe haemorrhage is possible, requiring haemostatic therapy for ≥6 days, orthopaedic interventions involving joints (ankle, knee, hip, wrist, elbow, shoulder), 3 rd molar extraction or extraction of ≥3 teeth or surgeries/conditions in which the patient's life is at stake.
